Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

DNA

Ribbon Biolabs raises $20 million to commercialize enzymatic DNA synthesis

by Matt Blois
February 4, 2022 | A version of this story appeared in Volume 100, Issue 5

Ribbon Biolabs has raised $20 million in series A funding to commercialize its enzymatic DNA synthesis technology. The Vienna-based firm says it plans to set up production facilities and expand into the US. Ribbon’s goal is to make extremely long strands of DNA, which is difficult to do with existing phosphoramidite chemistry, for synthetic biology companies. California-based Molecular Assemblies has raised more than $30 million and also hopes to enzymatically synthesize long DNA strands.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.